In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1908-1910

  Hamamoto, Kumiko ^a   Shimizu, Takashi ^a   Fujimoto, Naoyuki ^a   Zhang, Ye ^a   Arai, Sumio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; HUMAN; JAPAN; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA PNEUMONIAE; QUINOLINES;

EID: 0035023597     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1908-1910.2001     Document Type: Article

References (11)

1. Angela, B. B., C. K. Kari, and V. D. Gary. 1997. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 41:1594-1597.
2. Aral, S., Y. Gohara, A. Akashi, K. Kuwano, M. Nishimoto, T. Yano, K. Oizumi, K. Takeda, and T. Yamaguchi. 1993. Effects of new quinolones on Mycoplasma pneumoniae-infected hamasters. Antimicrob. Agents Chemother. 37:287-292.
3. Boswell, F. J, J. M. Andrews, and R. Wise. 1997. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and post antibiotic effect. Antimicrob. Agents Chemother. 41:1377-1379.
4. Cassell, G. H., K. B. Waites, M. S. Pate, K. C. Canupp, and L. B. Duffy. 1989 Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin. Diagn. Microbiol. Infect. Dis. 12:433-435.
5. Gohara, Y., S. Arai, A. Akashi, K. Kuwano, C. Tseng, S. Matsubara, M. Matumoto, and T. Furudera. 1993. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 37:1826-1830.
6. Grayston, J. T., H. M. Foy, and G. E. Kenny. 1969. The epidemiology of mycoplasma infections of the human respiratory tract, p. 651-682. In L. Hayflick (ed.), The mycoplasmatales and the L-phase of bacteria. Appelton-Century-Crofts, Amsterdam, The Netherlands.
7. Niitu, Y., S. Hasegawa, T. Suetake, H. Kubota, S. Komatsu, and M. Horikawa. 1970. Registance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J. Pediatr. 76:438-443.
8. Pearson, R. D., R. T. Steigbigel, H. T. Davis, and S. W. Chapman. 1980. Method for reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18:699-708.
9. Petersen, U., S. Bartel, K.-D. Bremm, T. Himmler, A. Krebs, and T. Schenke. 1996. The synthesis and biological properties of 6-fluoroquinolone-carboxylic acids. Bull. Soc. Chim. Belg. 105:689-699.
10. Tuomanen, E., 1986. Phenotypic tolerance: the search for β-lactam antibiotics that kill nongrowing bacteria.. Rev. Infect. Dis. 8:s279-s291.
11. Waites, K. B., G. H. Cassell, K. C. Canupp, and P. B. Fernandes. 1988. In vitro susceptibilities of mycoplasmas and ureaplasma macrolides and arylfluroquinolones. Antimicrob. Agents Chemother. 32:1500-1502.